# PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City
Canonical URL: https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-host-4q25-earnings-conference-call-on-february-24-2026-an-9d2e2bc4
Ticker: PRCT
Company: PROCEPT BioRobotics
Source: PROCEPT BioRobotics
Published: 2026-01-26 21:03 EST
## Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused...

## Article Body
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026 . The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time .

The Company also announced it will host an in-person investor day event on Wednesday, February 25, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time . Guests are encouraged to register in advance by clicking HERE . Registration is recommended to secure your spot.

A live webcast of both events, as well as an archived recording, will be available on the “Investors” section of the Company’s website at https://ir.procept-biorobotics.com . Each webcast will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States.

Important Safety Information All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/

Investor Contact: Matt Bacso VP, Investor Relations and Business Operations m.bacso@procept-biorobotics.com
## Recent Company News
- 2026-07-14 20:05 EST — [PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026](https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-report-second-quarter-2026-financial-results-on-august-4t-255b7bdd) — Source: PROCEPT BioRobotics
- 2026-05-28 12:00 EST — [PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval](https://biopharmsignal.com/news/PRCT/procept-biorobotics-advances-prostate-cancer-program-with-water-iv-study-enrollm-de942ff2) — Source: PROCEPT BioRobotics
- 2026-05-14 12:00 EST — [AUA Guidelines Strengthen Recommendation for Aquablation® Therapy](https://biopharmsignal.com/news/PRCT/aua-guidelines-strengthen-recommendation-for-aquablation-therapy-b17aee34) — Source: PROCEPT BioRobotics
- 2026-04-30 20:03 EST — [PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June](https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-attend-three-upcoming-investor-conferences-in-may-june-336852ab) — Source: PROCEPT BioRobotics
- 2026-04-29 20:03 EST — [PROCEPT BioRobotics Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PRCT/procept-biorobotics-reports-first-quarter-2026-financial-results-c24cd67e) — Source: PROCEPT BioRobotics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)